



Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing

Lorna W. Harries,^{1*} Dena Hernandez,^{2*} William Henley,³ Andrew R. Wood,¹ Alice C. Holly,¹ Rachel M. Bradley-Smith,¹ Hanieh Yaghootkar,¹ Ambarish Dutta,⁴ Anna Murray,¹ Timothy M. Frayling,¹ Jack M. Guralnik,⁵ Stefania Bandinelli,⁶ Andrew Singleton,² Luigi Ferrucci⁷ and David Melzer⁴

¹Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK

²Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA

³Centre for Health and Environmental Statistics, University of Plymouth, Plymouth PL4 8AA, UK

⁴Epidemiology and Public Health, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK

⁵Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, MD 20892-9205, USA

⁶Geriatric Unit, Azienda Sanitaria Firenze, Florence 50125, Italy

⁷National Institute on Aging, Clinical Research Branch, Harbor Hospital, Baltimore, MD 21225, USA

Summary

Aging is a major risk factor for chronic disease in the human population, but there are little human data on gene expression alterations that accompany the process. We examined human peripheral blood leukocyte *in-vivo* RNA in a large-scale transcriptomic microarray study (subjects aged 30–104 years). We tested associations between probe expression intensity and advancing age (adjusting for confounding factors), initially in a discovery set ($n = 458$), following-up findings in a replication set ($n = 240$). We confirmed expression of key results by real-time PCR. Of 16 571 expressed probes, only 295 (2%) were robustly associated with age. Just six probes were required for a highly efficient model for distinguishing between young and old (area under the curve in replication set; 95%). The focused nature of age-related gene expression may therefore provide potential biomarkers of aging. Similarly, only 7 of 1065 biological or metabolic pathways were age-associated, in gene set enrichment analysis, notably including the processing of messenger RNAs (mRNAs); [$P < 0.002$, false discovery rate (FDR) $q < 0.05$]. This is supported by our observation of age-associated disruption to the balance of alternatively expressed isoforms for selected genes, suggesting that modification of mRNA processing may be a feature of human aging.

Key words: aging; cell senescence; mRNA processing; gene expression; predictive model.

Correspondence

Dr Lorna W. Harries, Peninsula College of Medicine and Dentistry, Barrack Rd, Exeter EX25DW, UK. Tel.: 44 1392 406749; fax: 44 1392 406767; e-mail: Lorna.Harries@pms.ac.uk

*These authors contributed equally to this publication.

Accepted for publication 31 May 2011

Introduction

Advancing age is a major risk factor for many common diseases, including type 2 diabetes, cardiovascular disease, and many cancers (Butler *et al.*, 2008). However, aging is characterized by progressively rising heterogeneity, with some people becoming frail in their 70s while others remain fit into their 90s or even longer. Characterizing the changes underpinning the heterogeneity of aging processes at a molecular level has been a long-held goal.

One theory of aging is that random and widespread unrepaired damage to DNA (and other molecules) accumulated over a lifetime may cause cellular senescence (Gensler *et al.*, 1981), but it has not been established whether such damage is associated with large-scale alterations of gene expression in the aged human population. Alteration to highly sequence-dependent processes such as mRNA processing (Cartegni *et al.*, 2002) has been suggested in previous studies (Yannarell *et al.*, 1977; Meshorer & Soreq, 2002), but to date, there are little human data to assess this empirically. Several age-related diseases are known to be caused by alterations in the splicing patterns of the mRNA transcripts, including the Hutchison Gilford progeria syndrome, where premature aging is caused by a synonymous mutation (G608G) in the Lamin A (*LMNA*) gene, which obstructs the normal post-translational processing of the protein product and leads to the premature aging phenotype (Eriksson *et al.*, 2003). Similarly, alterations in the relative balance of alternatively expressed microtubule-associated protein tau (*MTAP*) isoforms are a feature of Alzheimer's disease-related tauopathies. (Chen *et al.*, 2010).

Gene expression arrays provide a powerful technology for identifying age-related alteration to the levels of gene transcripts in a comprehensive genome-wide way. Identification of individual transcripts and functionally coherent gene sets that are under- or over-expressed with aging in humans would provide key insights into the mechanisms of aging processes and age-related disease (Zahn *et al.*, 2006). This may provide a 'biomarker signature' for monitoring the effects of interventions to slow age-related changes, in an easily accessible tissue, peripheral blood leukocytes.

A variety of age-related expression analyses in cell lines or stored cell material have been reported, although results have had limited reproducibility (de Magalhaes *et al.*, 2009). This is likely to be due to the small sample sizes in previous studies and to the sensitivity of mRNA transcripts to variation in aspects of storage and handling (Min *et al.*, 2010). It is clear that identifying robust changes in age-related gene expression in humans will depend on large numbers of samples collected with optimal sample handling, so that results reflect *in-vivo* mRNA expression. Blood-derived leukocytes are a relevant tissue for the study of *in-vivo* aging processes in humans, as 'immunosenescence' is well described (Gruver *et al.*, 2007). Blood is likely to remain the principal accessible 'live' tissue for large-scale *in-vivo* expression studies and clinical analysis in humans. Blood-derived white cell transcriptome studies have already proved valuable in identifying signatures of major diseases and drug responses some with promising clinical applications (Dumeaux *et al.*, 2010).

We used a well-characterized population representative cohort, the InCHIANTI aging study (Ferrucci *et al.*, 2000), to examine transcriptome-wide alterations in gene expression associated with chronological age in samples from 698 individuals by microarray analysis. We predicted

widespread transcriptomic alterations with advancing age, and that inflammatory or immune function genes would be prominent in our results given our choice of target tissue (peripheral white blood cells). We aimed to identify both the most deregulated individual transcripts, but also the most deregulated gene sets grouped into biological pathways.

We found that although the largest single-transcript associations in human peripheral blood leukocytes do indeed include genes involved in inflammation or immune function, widespread alterations in gene expression levels were not apparent. In fact, only a very small proportion (295 of 16 571 transcripts; 2%) of transcripts demonstrated robust age-related differences in gene expression. Furthermore, a statistical model using just 6 of the top 25 transcripts was able to classify samples into 'young' or 'old' with high precision. These six transcripts may provide a biomarker set to monitor interventions aimed at slowing aging. Gene set enrichment analysis (GSEA) (a method to determine whether specific molecular or functional pathways are associated with a given trait) demonstrated that the pathways most disrupted by human aging include genes involved in messenger RNA splicing, polyadenylation, and other post-transcriptional events. This was accompanied by specific changes in the ratios of expression between isoform-specific transcripts for selected genes in our extended analysis. Deregulation of mRNA processing pathways may comprise a mechanism involved in human cellular aging.

Results

A small proportion of transcripts demonstrate marked age-related expression differences

A total of 16 571 transcripts gave reliable signals above background ($P \leq 0.01$) in > 5% of the sample population following QC of microarray data and were selected for analysis of gene expression alterations with age. The cohort was divided into discovery and test sets, based on analytical batch. Individual probes were only considered to be associated with chronological age (with adjustment for major confounders) if they reached a false discovery rate (FDR) $q < 0.001$ in the discovery set and also replicated in the test set with an FDR $q < 0.05$. Of 16 571 transcripts, we identified gene expression differences with age in only 2%; 360 probes in the discovery set, of which 295 replicated in our test set (see Table S1). Fifty (18%) of differentially expressed transcripts were up-regulated and 245 were down-regulated. Analysis of the extremes of the age distribution only (< 50 years ($n = 93$) vs. > 80 years ($n = 232$)) yielded only 53 probes associated with age, supporting our observation that human aging is associated with large-scale alterations in the expression of only a small number of transcripts.

The chemokine receptor 6 (*CCR6*), chemokine receptor 7 (*CCR7*), and *CD27* genes, previously associated with age and immunosenescence




Fig. 1 The expression of key genes with age. The figure shows the association between probe signal intensity (arbitrary units; Y-axis) and age (years; X-axis) for three genes known to be associated with age; *CD27*, chemokine receptor 6, and *CCR7* (a–c), the top three down-regulated genes in our study; leucine-rich repeat neuronal protein 3, *CD248*, and lymphoid enhancer-binding factor 1 (d–f) and the top three up-regulated genes in our study; vesicle-associated membrane protein 5, *GBP1*, and signal transducer and activator of transcription 1 (g–i).

Table 1 The most strongly (a) down-regulated (b) up-regulated genes with advancing age, by discovery and replication set

Number (by discovery <i>P</i> -value)	Probe	Probe ID	Discovery set			Replication set		
			Age coefficient	<i>P</i> -value	FDR <i>q</i> -value	Age coefficient	<i>P</i> -value	FDR <i>q</i> -value
1	LRRN3	ilmn_1773650	-0.0058	9.20E-32	8.20E-28	-0.0067	3.70E-16	2.20E-12
2	CD248	ilmn_1726589	-0.003	3.40E-27	1.50E-23	-0.0032	1.20E-17	1.40E-13
3	LRRN3	ilmn_2048591	-0.0029	1.80E-23	5.40E-20	-0.0023	1.30E-06	5.00E-04
4	LEF1	ilmn_2213136	-0.0124	4.20E-16	9.30E-13	-0.0131	7.60E-09	1.20E-05
5	LEF1	ilmn_1679185	-0.0131	2.80E-15	5.00E-12	-0.0146	4.20E-09	8.70E-06
6	NELL2	ilmn_1725417	-0.0055	8.80E-15	1.30E-11	-0.0056	2.70E-08	3.10E-05
7	ABLIM1	ilmn_1785424	-0.0092	2.00E-14	2.50E-11	-0.0089	5.90E-07	3.00E-04
8	FAM102A	ilmn_2401779	-0.0055	3.20E-14	3.60E-11	-0.006	9.00E-09	1.30E-05
9	CCR6	ilmn_1690907	-0.0024	2.40E-13	2.30E-10	-0.0022	1.10E-05	2.30E-03
10	ZSCAN18	ilmn_1654946	-0.004	7.10E-13	5.80E-10	-0.0043	7.70E-08	6.70E-05
11	BZW2	ilmn_1676548	-0.0016	7.80E-13	6.20E-10	-0.001	2.30E-03	5.68E-02
12	CCR7	ilmn_1715131	-0.0164	1.20E-12	8.10E-10	-0.0228	5.80E-10	1.70E-06
13	LTB	ilmn_2376204	-0.0076	1.20E-12	8.40E-10	-0.0084	2.10E-08	2.70E-05
14	GRAP	ilmn_2264011	-0.0091	1.60E-12	1.00E-09	-0.0099	4.90E-07	3.00E-04
15	HGFL	ilmn_1719986	-0.011	2.10E-11	1.10E-08	-0.0127	1.70E-06	6.00E-04
16	PASK	ilmn_1667022	-0.0041	2.90E-11	1.50E-08	-0.0055	5.30E-07	3.00E-04
17	KIAA1147	ilmn_2355033	-0.0044	3.10E-11	1.60E-08	-0.005	2.10E-05	3.50E-03
19	ABLIM1	ilmn_2396672	-0.0027	4.30E-11	2.00E-08	-0.0034	1.70E-06	6.00E-04
20	SYPL1	ilmn_2377174	-0.0038	6.00E-11	2.60E-08	-0.0041	8.20E-05	8.10E-03
21	CD27	ilmn_1688959	-0.0035	7.20E-11	2.90E-08	-0.0034	1.40E-06	6.00E-04
22	DQ894085	ilmn_1680618	-0.0048	7.40E-11	3.00E-08	-0.0059	1.10E-07	8.40E-05
23	DKC1	ilmn_1671257	-0.0033	1.60E-10	5.80E-08	-0.0028	2.00E-04	1.47E-02
24	FAIM3	ilmn_1775542	-0.0123	1.60E-10	5.90E-08	-0.0126	2.60E-05	4.00E-03
25	CDR2	ilmn_1720270	-0.0022	2.40E-10	8.60E-08	-0.0029	7.40E-08	6.60E-05
26	ATM	ilmn_2370825	-0.0063	3.50E-10	1.20E-07	-0.0063	3.60E-03	7.25E-02
18	VAMP5	ilmn_1809467	0.0092	3.70E-11	1.80E-08	0.0073	7.60E-05	7.60E-03
42	GBP5	ilmn_2114568	0.0107	4.60E-09	9.50E-07	0.0072	1.11E-02	1.21E-01
48	STAT1	ilmn_1691364	0.012	8.60E-09	1.60E-06	0.0133	2.80E-05	4.10E-03
51	WARS	ilmn_1727271	0.009	1.50E-08	2.40E-06	0.0088	2.00E-04	1.41E-02
58	WARS	ilmn_2337655	0.0093	2.10E-08	3.30E-06	0.009	5.00E-04	2.41E-02
74	MT2A	ilmn_1686664	0.0131	6.30E-08	7.50E-06	0.014	7.00E-05	7.20E-03
77	CTSA	ilmn_1719286	0.0049	8.40E-08	9.40E-06	0.0057	2.00E-04	1.46E-02
82	SLC27A3	ilmn_1719627	0.0034	9.60E-08	1.00E-05	0.0026	4.80E-03	8.42E-02
84	FBXO6	ilmn_1701455	0.0037	1.20E-07	1.20E-05	0.0024	3.45E-02	2.00E-01
95	VCAN	ilmn_1687301	0.0079	1.60E-07	1.50E-05	0.0065	3.30E-03	6.93E-02
100	EIF4G3	ilmn_1775692	0.0017	2.10E-07	1.90E-05	0.0016	2.60E-03	6.08E-02
101	DUSP3	ilmn_1797522	0.0046	2.30E-07	2.00E-05	0.0045	2.80E-03	6.30E-02
114	GZMH	ilmn_1731233	0.017	5.70E-07	4.30E-05	0.0216	8.10E-06	1.90E-03
123	PSMB9	ilmn_2376108	0.0082	8.90E-07	6.00E-05	0.0061	1.18E-02	1.25E-01
133	TTC38	ilmn_2059886	0.0029	1.20E-06	7.30E-05	0.0041	7.10E-05	7.30E-03
148	SYT11	ilmn_1717934	0.0046	2.10E-06	1.00E-04	0.0049	1.90E-03	5.08E-02
142	FCGR1A	ilmn_2261600	0.0095	1.70E-06	1.00E-04	0.0075	1.01E-02	1.16E-01
157	WIP1	ilmn_1781386	0.0014	2.90E-06	2.00E-04	0.0013	3.70E-03	7.31E-02
164	P2RX7	ilmn_1759326	0.0017	3.20E-06	2.00E-04	0.0022	1.00E-03	3.80E-02
184	TTC38	ilmn_1692464	0.0042	5.20E-06	2.00E-04	0.0066	2.00E-04	1.27E-02
192	H3F3A	ilmn_2402930	0.0047	6.00E-06	2.00E-04	0.0034	3.42E-02	1.99E-01
171	STOM	ilmn_1766657	0.0052	4.00E-06	2.00E-04	0.0054	1.90E-03	5.13E-02
176	STAT1	ilmn_1690105	0.0063	4.30E-06	2.00E-04	0.0073	2.00E-04	1.51E-02
182	MT1A	ilmn_1691156	0.0077	4.80E-06	2.00E-04	0.0092	1.00E-03	3.71E-02
205	B3GAT1	ilmn_1761093	0.0012	8.80E-06	3.00E-04	0.0018	2.90E-06	9.00E-04

The gene and probe identities are given in each case. The age coefficient, the significance *P*-value, and the false discovery rate (FDR) *q*-value are also given.

ABLIM1, actin-binding LIM protein 1; CCR6, chemokine receptor 6; LEF1, lymphoid enhancer-binding factor 1; LRRN3, leucine-rich repeat neuronal protein 3; STAT1, signal transducer and activator of transcription 1; VAMP5, vesicle-associated membrane protein 5.

(Yung *et al.*, 2007), were also found to be associated with age in our study. Plots of microarray signal intensity against increasing age (Cloud plots) for these, and the top 3 up- and down-regulated genes in our analysis, namely leucine-rich repeat neuronal protein 3 (*LRRN3*), endosialin (*CD248*), lymphoid enhancer-binding factor 1 (*LEF1*), vesicle-associated

membrane protein 5 (*VAMP5*), guanylate binding protein 5 (*GBP5*), and signal transducer and activator of transcription 1 (*STAT1*), are presented in Fig. 1. The 25 most up-regulated and the 25 most down-regulated transcripts are shown in Table 1. The most statistically significant association between age and gene expression was for the *LRRN3* gene

($P = 8.2 \times 10^{-28}$), thought to be involved in MAPK activity and endocytosis.

It is possible that some of the effects we note may result from increases in age-related variation in inter-individual expression levels. However, the Breusch Pagan test of conditional heteroscedasticity did not provide evidence to support this hypothesis. The lowest P -value for the effect of age on residual expression variability failed to reach genome-wide significance before or after adjustment for age effects on mean expression (minimum $P = 3.2 \times 10^{-5}$, FDR $q = 0.18$). Therefore, these results provide no evidence for increased variability in inter-individual gene expression with age.

Six of the most deregulated 25 probes provide good discrimination between young and old

We then identified which of the 25 most strongly age-associated probes provide the best discrimination between a younger group (age < 65; $n = 107$ in discovery set) and older subjects (age ≥ 75 ; $n = 308$ in discovery set). We used multivariable logistic regression modeling to select probes that add significantly to classification (see methods, statistical analysis). Our final model included six genes; *LRRN3*, *CD248*, *CCR6*, *GRAP* (growth factor receptor-bound protein 2 related adaptor protein), *VAMP5*, and *CD27*, which together explained 63% of the age-group associated variation (Table S2). The multivariable logistic regression model was used to generate an age-group classification for subjects in the independent replication set. The ROC (Receiver Operating Characteristic) curve (Fig. S1) shows that this small subset of genes is sufficient to achieve exceptionally strong separation between older and younger subjects (ROC area under the curve, (AUC) = 96% in discovery set and 95% in validation set). The AUC for alternative age-group comparisons within our replication set is 91% for < 60 vs. age ≥ 60 and 84% for the age 60–69 vs. age 70–79.

Key expression changes replicate when assayed by an alternative method; TaqMan low-density array (TLDA) analysis

Taqman low-density array quantitative real-time PCR provides a robust independent laboratory technique to validate array results and provides more accurate estimates of effect sizes. We validated 27 of the most

differentially expressed genes identified by microarray analysis using TLDA quantitative real-time PCR. Of the 27 genes tested, 22 showed clear differences in gene expression with age (see Table S3). Representative box plots (comparing data for 49 respondents aged 30–44 years and 50 respondents aged 85–104) for one gene previously associated with aging (*CCR7*) (Yung *et al.*, 2007) and two of the top associations found in our study, *LRRN3* and *LEF1*, are given in Fig. 2. Of those that did not replicate, two had no detectable expression (*AKTIP* and *IGLL1*) and three (*RPS5*, *E2F5* and *VEGFB*) showed evidence of a trend for altered expression, but were not statistically significant. These transcripts were at the lower limit of statistical significance following Bonferroni correction for multiple testing ($P = 1 \times 10^{-5}$) on the microarray data, indicating that some of the genes located at the limits of statistical significance may not represent genuine hits.

For our top gene (*LRRN3*), the mean expression intensity in the young sample (aged 30–44 years) was 1.65 (95%CI for the mean 1.36–1.94), compared with 0.53 (CI 0.44–0.62) in the older sample (85–104 years), a highly significant difference ($P < 0.0001$) (Table S3). This *LRRN3* change represented a very large reduction, i.e. the expression in the older sample is 32% of that in the young. In our TLDA-validated genes, the expression in the older group ranged from 32% to 175% of that in the young.

Gene set enrichment analysis (GSEA) reveals that the major pathways affected by age in humans relate to post-transcriptional processing of messenger RNA transcripts

We applied GSEA (Subramanian *et al.*, 2005) to identify pathways (rather than individual transcripts) that are associated with age. We examined 1065 predefined gene sets, grouped by (mainly Gene Ontology) classification of molecular function or biochemical processes. Of the 1065 pathways examined, only seven pathways were significantly associated with age, after accounting for the multiple statistical testing (FDR q -value < 0.05) (Table 2). These were total RNA binding (nominal P -value < 0.001), mRNA metabolic process ($P < 0.001$), mRNA binding ($P < 0.001$), RNA splicing ($P < 0.001$), mRNA processing ($P < 0.001$), ribonucleoprotein complex biogenesis and assembly ($P < 0.001$), and chromatin assembly or disassembly ($P = 0.002$). Figure 3 shows the enrichment plot for the RNA splicing pathway. Leading edge analysis (which identifies specific genes driving observed pathway associations) revealed that there was significant overlap between genes in these




Fig. 2 Box plots showing gene expression changes obtained by TaqMan low-density array (TLDA). This figure demonstrates the difference in expression levels between young (30–44 years; $n = 49$) and old (85–104 years; $n = 50$) individuals as assessed by TLDA analysis. Gene expression levels expressed relative to the endogenous controls are given on the Y-axis, and the patient group (young or old) are given on the X-axis.

Significance rank with age	Pathway	Source of pathway definition	Size (number of genes in pathway)	NES	Nominal <i>P</i> -value	FDR <i>q</i> -value
1	RNA binding	GO	200	-2.00092	< 0.001	0.023
2	mRNA metabolic processes	GO	73	-1.92912	< 0.001	0.027
3	mRNA binding	GO	19	-1.93444	< 0.001	0.029
4	RNA splicing	GO	75	-1.95339	< 0.001	0.029
5	mRNA processing	GO	63	-1.8974	< 0.001	0.03
6	Ribonucleoprotein complex biogenesis/assembly	GO	68	-1.89765	< 0.001	0.036
7	Chromatin assembly or disassembly	GO	20	-1.95669	0.002	0.041
8	RNA processing	GO	136	-1.98935	< 0.001	0.057
9	Protein RNA complex assembly	GO	56	-1.82204	0.004	0.057
10	DNA replication	GO	73	-1.82487	0.002	0.063
11	DNA-dependent DNA replication	GO	37	-1.77582	0.004	0.085
12	Purine metabolism	KEGG	101	-1.95911	< 0.001	0.089
13	Organelle lumen	GO	346	-1.66622	0.002	0.091
14	Negative regulation of programmed cell death	GO	110	-1.71244	< 0.001	0.099

Size refers to the number of genes in the pathway. The false discovery rate (FDR) is given by the *q*-value and the statistical significance by the *P*-value.

GO, gene ontology subset; KEGG, Kyoto encyclopedia of genes and genomes; NES, normalized enrichment score for each gene.




Fig. 3 Gene set enrichment analysis plot for the RNA splicing pathway. The Y-axis gives the enrichment score for an association with age in the top panel and the ranked list matrix in the bottom panel. The X-axis refers to the rank of each gene in the ordered dataset. Each vertical line in the central portion of the figure refers to one gene within the pathway. The position of each line relative to the central dashed line indicates whether the gene is positively or negatively correlated with age. Positive correlations with age (age-pos) locate to the left of the figure, and negative correlations with age (age-neg) locate to the right side of the figure. The dashed line represents the null point, where a gene demonstrating no positive or negative correlation would appear. RLM, Ranked List Metric; ES, Enrichment score.

pathways, and that four pathways relate essentially to the same process; post-transcriptional processing of messenger RNA transcripts (Fig. S2). The remaining pathways involve genes responsible for opening or closing

Table 2 Gene set enrichment analysis plots for potential age-associated gene sets, for molecular function or biochemical process pathways

the chromatin structure to allow (or disallow) transcription, and genes involved in the production and action of ribosomes, permitting translation of the processed messenger RNA transcript. GSEA also revealed two biological function gene sets possibly up-regulated in older people (extracellular region genes $P = 0.004$ and ion transport genes $P = 0.008$), although neither were significant when accounting for multiple testing (FDR *q*-value = 0.197 and *q*-value = 0.207, respectively).

Evidence of age-related changes in isoform ratios with advancing age

Given the prevalence of genes involved in mRNA processing in our GSEA results, we sought to determine whether the pattern of alternatively expressed isoforms might therefore be disrupted with age. Of the ten genes fulfilling our criteria for study, we found evidence of disruption to splicing patterns in seven of these [actin-binding LIM protein 1 (*ABLIM1*), *STAT1*, *CD79a* molecule, immunoglobulin-associated alpha (*CD79A*), heat shock 60kDa protein 1 (*HSPD1*), clusterin-associated protein 1 (*CLUAP1*), lysosomal-associated membrane protein 2 (*LAMP2*), and *SON* DNA-binding protein (*SON*)], and the eighth, caspase 8 (*CASP8*) was near significant at $P = 0.097$ (Fig. S3; Table 3). The *ABLIM1* gene codes for four alternatively processed reference sequence isoforms, NM_002313.5, NM_001003407.1, NM_001003408.1, and NM_006720.3. Comparison of the amount of NM_006720.3 relative to the other three isoforms reveals a progressive increase with age (correlation coefficient 0.0009; $P \leq 0.0001$; supplementary Fig. S3). The *STAT1*, *CD79A*, *HSPD1*, *CLUAP1*, *LAMP2*, and *SON* genes exhibit similar disturbances to isoform ratios with advancing age (Table 3).

In a separate analysis, we sought to provide extra evidence for disruption of splicing with increasing age using a more accurate quantitative technique, real-time PCR. We selected alternatively spliced genes from the top 250 genes most associated with age, for which commercial probes were available. Of eight genes tested in the fifty youngest and fifty oldest individuals, we found evidence for disruption to the ratio of alternatively expressed isoforms in 3 (*EFNA1*, *GPR18*, and *VCAN*; $P = 0.05$, 0.05, and 0.02–0.04, respectively, depending on the comparison), with

Table 3 Analysis of the effect of age on the expression of alternatively spliced isoforms

Gene	ID	Isoform	Mean	SE	Comparison	Coeff	CI	CI	P-value
ABLIM1									
1	ilmn_1731610	NM_006720.3	102.29	6.21					
2	ilmn_2396672	All	115.61	10.49	1/2	0.0009	0.0006	0.0012	< 0.0001
3	ilmn_1785424	All	209.54	53.73	1/3	0.0032	0.0027	0.0037	< 0.0001
STAT1									
4	ilmn_1777325	NM_007315.3	317.9793	145.709					
5	ilmn_1691364	NM_139266.2	715.9618	329.8048	4/5	-0.0026984	-0.0033706	-0.0020263	0.0033706
CD79A									
6	ilmn_2410371	NM_001783.3	94.26653	4.791344					
7	ilmn_1734878	All	338.5959	213.6811	6/7	0.0028078	0.0021338	0.0034817	0.0021338
HSPD1									
8	ilmn_1784367	NM_002156.42	96.76617	3.201362					
9	ilmn_1766713	All	142.1247	19.87898	8/9	0.0012785	0.0008516	0.0017055	0.0008516
CASP8									
10	ilmn_1750596	NM_024793.1	100.70	3.63					
11	ilmn_2242491	NM_024793.1	10361.48	1983.51	7/8	0.0000	0.0000	0.0000	< 0.0001
LAMP2									
12	ilmn_1752351	NM_013995.2	238.35	52.02	12/14	-0.0004	-0.0011	0.0002	0.208
13	ilmn_2279961	NM_013995.2	261.87	83.04	12/13	-0.0016	-0.0030	-0.0002	0.027
14	ilmn_1673282	NM_002294.2	354.04	97.12					
MAX									
15	ilmn_1695633	NM_145116.1	93.97	4.54	15/16	-0.0001	-0.0003	0.0002	0.578
16	ilmn_1802457	NM_145114.1	107.29	3.99	15/17	-0.0002	-0.0004	0.0001	0.155
17	ilmn_1706546	NM_145113.1	108.31	5.55	16/17	-0.0001	-0.0004	0.0002	0.423
SON									
18	ilmn_1663090	NM_032195.1	106.31	4.13					
19	ilmn_2247664	NM_138927.1	200.96	45.44	18/19	0.0017	0.0011	0.0023	< 0.0001
WTAP									
20	ilmn_1734544	NM_004906.3	238.35	52.02					
21	ilmn_2279339	NM_004906.3	261.87	83.04	20/22	0.0003	-0.0002	0.0009	0.208
22	ilmn_1657618	NM_152857.1	354.04	97.12	21/22	0.0015	-0.0014	0.0044	0.305

The ratio of alternatively expressed isoforms of specific genes in relation to increasing age is given in the table above. Association with age is calculated by logistic regression. The analysis was carried out on 689 individuals.

ABLIM1, actin-binding LIM protein 1; CASP8, caspase 8; CI, confidence intervals; coeff, correlation coefficient; HSPD1, heat shock 60 kDa protein 1; ID, probe identity; isoform, transcript identity; LAMP2, lysosomal-associated membrane protein 2; Mean, mean ratio; SE, standard error, comparison indicates which comparisons were made for the analysis; STAT1, signal transducer and activator of transcription 1.

the 4th (*BCL11B*) being very near significance at $P = 0.053$ (Fig. S4, Table 4).

Discussion

In this study, we present the first assessment of age-related alterations in gene expression in a large population-based cohort. Contrary to our expectations, we found relatively few age-associated transcripts, but these did include several genes associated with inflammation or immune senescence, as expected. Gene set enrichment analysis indicated that only a very small number of molecular or biological function pathways were robustly associated with advancing age, comprising mainly genes involved in the processing and maturation of messenger RNA transcripts. This finding was supported by subsequent observation of age-associated differences in the balance of alternatively expressed isoforms, as suggested by previous studies (Yannarell *et al.*, 1977; Meshorer *et al.*, 2002). Our results suggest that modification of messenger RNA (mRNA) processing may comprise an important feature of human aging.

Very few genes (295 of 16 571; 2% of transcripts identified) demonstrated strong and robust associations with advancing age in our study. Power calculations based on the method of Hsieh *et al.* (1998) indicate

that the relatively large sample available ($n = 458$ in discovery set) is sufficient to detect effect sizes for transcripts statistically 'explaining' as little as 5.3% of the variation in age. Thus, if we have not detected other genes because of 'noisy' data, individual effect sizes for such genes are likely to be of limited biological significance.

The transcripts with the largest effect sizes comprise a set of peripherally expressed biomarkers of the aging process, some substantially stronger than those currently known. Transcripts such as *CCR6*, *CCR7*, and *CD27*, previously reported to be involved in immune senescence (Yung *et al.*, 2007), were also associated with age in our study (Fig. 1). As predicted, genes showing the largest differential in expression with age were involved in inflammatory responses, or immune function (de Magalhaes *et al.*, 2009). Genes related to the human immune system, e.g. *LRRN3*, *CD248*, *LEF1*, *CCR6*, *CCR7*, *CD27*, and *LTB* (lymphotoxin beta – TNF superfamily, member 3), expressed lower levels of mRNA transcripts with increasing age in our cohort, which is in agreement with other studies in human peripheral lymphocytes (Hong *et al.*, 2008). This is not unexpected given that our study tissue was white blood cells. Reduced expression of these genes with age implies that the mechanisms involved are likely to mark the process of 'immunosenescence,' characterized by reduced chemotactic migration of the immune mediator cells, lowered

Table 4 Genes showing disruption to the balance of alternatively spliced isoforms by real-time PCR

Gene	ID	Isoform	Mean	SE	Comparison	Coeff	CI	CI	P-value
BCL11B									
1	hs01102259_m1	NM_138576.2	1.058325	0.349844					
2	hs01112109_m1	NM_022898.1	1.062152	0.36903	1 over 2	0.00125	-0.0000175	0.0025182	0.053
EFNA1									
3	hs00358887_m1	NM_004428.2	1.376142	1.084887					
4	hs01020895_m1	NM_182685.1	1.315693	1.144735	3 over 4	-0.00394	-0.0078545	-0.0000253	0.049
GPR18									
5	hs00245542_m1	NM_001098200.1	1.070176	0.407375					
6	hs01649814_m1	NM_005292.3	1.081336	0.446335	5 over 6	0.00189	3.60E-06	0.0037757	0.05
VCAN									
7	hs01007937_m1	NM_001164097.1	1.098376	0.559999					
8	hs01007941_m1	NM_001126336.2	1.086235	0.457961	7 over 8	0.002647	0.0001322	0.0051619	0.039
9	hs01007943_m1	NM_001164098.1	1.23125	0.845863	9 over 7	-0.01048	-0.0193924	-0.0015691	0.022
10	hs01007944_m1	NM_004385.4	1.210006	0.92149	9 over 10	-0.00778	-0.0154129	-0.0001444	0.046
ANXA7									
11	hs00244504_m1	NM_004034.2	1.066305	0.388382	12 over 11				
12	hs00559416_m1	NM_0011156.3	1.929157	8.420153	11 over 12	-0.00219	-0.0057466	0.0013578	0.223
CXCR5									
13	hs00540527_s1	NM_001716.3	1.116763	0.540786	14 over 13				
14	hs00540548_s1	NM_032966.1	1.100177	0.497535	13 over 14	-0.0011	-0.0026285	0.0004256	0.156
IGL6ST									
15	hs01006741_m1	NM_002184.3	1.068342	0.397245	16 over 15				
16	hs01006742_m1	NM_175767.2	1.898088	5.478007	15 over 16	0.004691	-0.0045713	0.0139524	0.317
PUM1									
17	hs00982771_m1	NM_001020658.1	1.031583	0.253846					
18	hs00985111_m1	NM_014676.2	1.091318	0.995023	17 over 18	0.001596	-0.0003754	0.0035682	0.111

The ratio of alternatively expressed isoforms of specific genes as determined by real-time PCR is correlated with age in the table above. Association with age is calculated by logistic regression. The analysis was carried out on 100 individuals.

CI, confidence intervals; coeff, correlation coefficient; ID, probe identity; isoform, transcript identity; Mean, mean ratio; SE, standard error, comparison indicates which comparisons were made for the analysis.

activation and differentiation of lymphocytes and macrophages with reduced synthesis of immunoglobulins and increased apoptosis of immune cells. Our finding of a strong association of lower *CCR7* gene expression with advancing age validates the findings from Yung *et al.* (2007).

Our findings should also be considered in the context of age-related changes in lymphocyte composition. Some age-associated transcripts may be expressed in different white cell subtypes; the *CD28*, *CCR7*, and *GZMH* genes are differentially expressed in CD8⁺ CD28⁺ T-cells compared with CD8⁺ CD28⁻ T-cells, the ratio of which is known to alter with age (Lazuardi *et al.*, 2009). Some of the alterations in gene expression may therefore derive from differences in the composition of the lymphocyte population in older people. What remains to be seen is whether any of alterations in lymphocyte composition are themselves attributable to the altered gene expression patterns we have demonstrated.

Several other factors have been implicated in aging or longevity, including alterations to nutrient sensing pathways, such as insulin or TOR signaling, oxidative stress/DNA repair, inhibition of respiration, reproductive system signaling, and telomere-related mechanisms (Kenyon, 2010). Accordingly, genes representing some of these processes are evident among the top 100 associations we have identified. These include the *PASK*, *FOXO1*, *DKK1*, and *MYC* transcripts, involved in energy sensing, insulin signaling, telomere maintenance, and ribosomal biogenesis, respectively (Gu *et al.*, 2009; Schlafli *et al.*, 2009; Dai *et al.*, 2010; Smith *et al.*, 2010).

The association of individual gene transcripts with age does not account for correlations between markers. We developed a bi-class discriminant model that identified a set of six transcripts within the top 25

strongest associations that form a potential predictive signature of chronological aging (Table S2; Fig. S1). This model was exceptionally good at classifying young and old [the area under ROC curve was 96% in our discovery set, and this was only slightly diminished (95%) in the independent replication set]. The six genes in the predictive group comprise genes involved in immunity or inflammation (*LRRN3*, *CD27*, *CCR6*) but also include some that are involved in the maintenance or development of muscle tissue (*VAMP5*; myobrevin) or in vascularization (*CD248*, endosialin). Future versions of this discriminant model might attempt to disentangle 'aging' from age-related disease effects: however, doing so is conceptually and practically difficult, but the relative robustness of the model for different age-group comparisons suggests that the transcript set is not merely distinguishing disease-free, from diseased, individuals.

Gene set enrichment analysis revealed a striking restriction in the number of pathways that were associated with age in our dataset; only seven of 1065 molecular or biological function pathways are robustly associated with age. Four of these pathways identified are involved in mRNA processing (namely mRNA binding, mRNA processing, mRNA processing reactome, and RNA splicing). Three of the age-associated pathways we identified (RNA binding, RNA splicing, and ribosome biogenesis and assembly) were also noted in previous GSEA analyses in mice (Southworth *et al.*, 2009). Differences between our results and the studies may arise from differences between species in the aging process, or from differences in the tissue specificity of changes.

RNA processing is the mechanism by which the initial RNA products transcribed from genes are prepared for eventual translation. This includes removal of introns and addition of the poly-A tail and 5' Cap structures (Keene, 2010). These processes occur simultaneously and

ensure diversity of the mRNA transcriptome and determine stability and half-life of the mRNA transcripts (Fong & Bentley, 2001). In our GSEA analysis, transcripts responsible for all aspects of mRNA processing were present in the core-enriched fraction of the pathway (Table S4 online), with a surprising amount of overlap between the groups (Fig. S2). The remaining pathways relate to the accessibility of the chromatin to transcription factors (chromatin assembly and disassembly) and to the processes that surround the translation of the mRNA transcripts (RNA-binding and ribonucleoprotein complex biogenesis and assembly), which is in keeping with previous observations of a reduction in rates of protein synthesis with age in humans and animal species (Ballard & Read, 1985; Kennedy & Kaerberlein, 2009).

Our observation that disruption to the proteins involved in mRNA processing appears to occur without widespread alterations in gene expression levels may indicate that while aged leukocytes *in-vivo* may be expressing most genes at comparable levels to those found in younger cells, there may be differences in the relative balance of splice products produced or increases in the occurrence of aberrantly spliced transcripts. In seven of ten alternatively spliced genes we studied, we found disruptions to the patterns of isoform expression with increasing age, and a near-significant result in one further case (Table 3). We also noted variation in splicing patterns with age by real-time PCR, finding alteration to the balance of alternatively expressed isoforms in 3 of 8 (38%) alternatively spliced genes, with the 4th very near significance. Our observation of very modest effects even in a very limited cohort of 100 people (7–37% alteration in the ratio of isoforms) suggests that the true level of splicing disruption may be higher than we report and warrants a more detailed, targeted study.

Whether or not the processing of a particular transcript is disrupted will depend on many factors, not least how many different sequence elements are necessary to ensure the usage of a particular splice junction. Presumably, highly regulated transcripts with weaker splice sites that are very dependent on additional sequence factors (such as exon splicing enhancers (Cartegni *et al.*, 2002)) may be more susceptible to age-accumulated DNA and RNA damage and thus more likely to show disruption of splicing and other related processes with age. Interestingly, two of the most deregulated splicing proteins in our microarray data, SFR6 (SRp55) and SRF51 (ASF/SF2) ($P = 1.3 \times 10^{-6}$ and 0.0001, respectively), were members of the SRF5 (Splicing Factor, Arginine/Serine-Rich) family of splicing factors, which are key players in maintaining the plasticity of the transcriptome by regulation of alternative splicing (Valcarcel & Green, 1996). This is particularly interesting because these proteins are key ligands for the exon splicing enhancer (ESE) motifs that regulate splice site choice in development and differentiation (Cartegni *et al.*, 2002). Their deregulated expression during the aging process may therefore manifest as a reduction in the adaptive capacity of the transcriptome.

Disruption to the mRNA processing machinery may also lead to an increase in the occurrence of unusual or aberrant splicing products, which of course would not be present on the microarray chip. This would not be an unexpected finding in an aging organism, given that they may arise from mutations in the DNA sequence elements that control splice site usage, or from alterations in the RNA transcript itself, which is very susceptible to damage by oxidative and other insult (Kong & Lin, 2010). Some of the proteosomal components that intercept and neutralize aberrant proteins produced from such transcripts were up-regulated in our data (*PMSB9*; FDR q -value = 0.008, $P = 6 \times 10^{-5}$, *PMSB10*; $q = 0.005$, $P = 0.0008$).

There is a growing body of evidence that results from peripheral blood white cells are also relevant to less accessible tissues (Tang *et al.*, 2003; Twine *et al.*, 2003; Achiron *et al.*, 2004). In some reports, the majority of

changes appeared to be in genes with little tissue-specific regulation, suggesting that most of the transcriptomic alterations with age might be generalized (Rodwell *et al.*, 2004; de Magalhaes *et al.*, 2009). This is supported by other evidence, where age-related expression differences were compared in brain, kidney, and muscle, in a population of 81 human subjects, and found to be conserved in each of these tissues (Zahn *et al.*, 2007). The age-related transcriptomic signature is also relatively stable; of the 50 top associations reported by Hong *et al.*, (2008), 32 of the 42 represented in our data also showed age-related differences, at least at $P \leq 0.05$ (data available from authors), despite the differences expected comparing our *in-vivo* leukocyte mRNA to mRNA from stored isolated lymphocytes. Lymphocytes are also the most appropriate tissue for the study of immune senescence, which is key to many chronic disease processes, including inflammation, and autoimmune alterations with age (Desai *et al.*, 2010).

Possible limitations of our study analysis include the deliberate absence of accounting for specific disease. This is because an increased susceptibility to disease is intrinsic to any definition of aging, and thus accounting for disease would risk controlling out the associations of interest (and also poses major practical difficulties with undiagnosed disease being common at older ages). Similarly, our study does not account for variation in the transcriptome of different blood cell subtypes. However, as noted above, our results are consistent with those from isolated lymphocytes (Hong *et al.*, 2008), and our approach avoids disruption to *in-vivo* expression patterns.

In conclusion, we present the first genome-wide assessment of age-related *in-vivo* leukocyte gene expression profiles in a large population-based study. As aging is associated with random damage to DNA (Gensler & Bernstein, 1981), we tested the hypothesis that this would result in widespread deregulation of gene expression. Instead, we found that human aging is associated with a small number of focused changes, mainly in individual genes associated with immune cell function. The major pathways associated with older age in humans were mainly involved with the processing of the primary RNA transcripts into mature mRNAs, an observation supported by our finding of age-related changes in the relative expression of alternatively expressed isoforms of example loci. We suggest that disruption to messenger RNA processing may comprise an important feature of aging in the human population.

Experimental procedures

Ethics statement

Ethical permission was granted by the Istituto Nazionale Riposo e Cura Anziani institutional review board in Italy. Participants gave informed consent to participate.

Cohort details

The InCHIANTI study (Ferrucci *et al.*, 2000) is a population-based, prospective epidemiological study of factors affecting aging, in the Chianti area (Tuscany) of Italy. The participants were originally enrolled in 1998–2000 and were interviewed and examined every 3 years. The recent 9-year follow-up examination involved 733 participants. Characteristics of the study cohort are given in Table 5.

RNA collection and extraction

Peripheral blood specimens preserving *in-vivo* RNA expression were collected at the 9-year follow-up (2008/9), using the PAXgene technology

	Discovery sample		Replication sample		Pooled sample	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Age (quartiles)						
30–68 years	121	26.42	59	24.58	180	25.79
69–78 years	141	30.79	72	30	213	30.52
79–82 years	91	19.87	43	17.92	134	19.2
83–104 years	105	22.93	66	27.5	171	24.5
Gender						
Men	211	46.07	102	42.5	313	44.84
Women	247	53.93	138	57.5	385	55.16
Site						
Greve	188	41.05	154	64.17	342	49
Bagno a Ripoli	270	58.95	86	35.83	356	51
Education						
Nothing	65	14.19	29	12.08	94	13.47
Elementary	199	43.45	123	51.25	322	46.13
Secondary	55	12.01	38	15.83	93	13.32
High school	62	13.54	25	10.42	87	12.46
University/professional	77	16.81	25	10.42	102	14.61
Pack years smoked (lifetime)						
None	249	54.37	130	54.17	379	54.30
< 20	97	21.18	56	23.33	153	21.92
20–39	71	15.50	30	12.50	101	14.47
40+	35	7.64	20	8.33	55	7.88
Missing	6	1.31	4	1.67	10	1.43
Waist circumference (cm)						
Mean (SD)	458	95.6 (12.4)	240	94.8 (11.5)	698	95.3 (12.1)

Table 5 Characteristics of the discovery and replication samples. Clinical characteristics and demographics of the study cohort are given

to preserve levels of mRNA transcripts as they were at the point of collection (Debey-Pascher *et al.*, 2009). RNA was extracted from peripheral blood samples using the PAXgene Blood mRNA kit (Qiagen, Crawley, UK) according to the manufacturer's instructions.

Whole transcriptome scan

Whole genome expression profiling of the samples was conducted using the Illumina Human HT-12 microarray (Illumina, San Diego, California, USA) as previously described (Zeller *et al.*, 2010). Preprocessing of microarray data is described in the Data S1.

Statistical analysis

Our dataset was subdivided on the basis of hybridization batch: a discovery dataset containing approximately two-thirds of the full sample ($n = 458$ individuals), and an independent replication set ($n = 240$ individuals). This is a form of test-set cross-validation, a common and well-established approach when assessing performance of classification models (Lubomirski *et al.*, 2007).

We calculated median centered gene expression levels on the \log_2 scale to ensure maximum overlap of profiles without altering their variance, in line with methodology used in previous studies (Idaghdour *et al.*, 2010). The relationship between gene expression and chronological age was tested using a linear regression model with (log-transformed) gene expression level as the dependent variable, chronological age (recorded at RNA extraction) as an explanatory variable, and with adjustment for potential confounders. Separate regression models were fitted for each of the full set of 16 571 probes which passed QC in the discovery dataset. We used the FDR to account for multiple testing, applying an FDR cut off

of $q \leq 0.001$ to select probes expressing differentially with age. Transcripts selected at the screening stage in the discovery set were tested for association with age in the replication dataset using the same model specification. The development of a bi-class discriminant model to identify the transcripts explaining the majority of the association with age is described in the Data S1.

All our analyses were adjusted for the following potential confounding factors on gene expression: gender; lifetime pack years smoked (in five categories: none, < 20 years, 20–39 years, 40 plus years, and missing); waist circumference (as a continuous trait); highest level of education attained (in five categories: none, elementary, secondary, high school, and university/professional); and study site [individuals were drawn from a rural village (Greve) and an urban population (Bagno a Ripoli)]. We also controlled for potential hybridization and/or amplification batch effects in all our analyses (Table S5).

TaqMan low-density array (TLDA) validation of microarray results

A subset of the cohort comprising the oldest men and women (85–104 years, $n = 50$) was compared with one comprising the youngest men and women (30–44 years, $n = 49$) in this analysis. Total RNA (100 ng) was reversed transcribed in 20- μ L reactions using the Superscript III VIL0 kit (Invitrogen, Paisley, UK), according to the manufacturer's instructions. RNA samples were then used for TLDA analysis. A list of target genes is given in Table S6. Each 32-gene set included four endogenous control genes which had been empirically validated as being unaffected by age on the basis of the microarray results; *18S*, *GUSB*, *PPIA*, and *IDH3B*. Reaction conditions are described in the Data S1.

Pathway analysis (GSEA)

Gene set enrichment analysis was performed to assess pathways or predefined gene sets associated with chronological age according to the method of Subramanian *et al.* (2005). 'Enrichment statistic' and 'Metric for ranking gene' parameters were configured to 'Weighted' and 'Pearson,' respectively. One thousand random permutations of the phenotype label were used to calculate the empirical *P*-values of each pathway. The gene sets with a nominal *P*-value < 0.01 and FDR of $\leq 25\%$ were considered as potential associated gene sets as previously described (Subramanian *et al.*, 2005). Gene symbols and the Illumina annotation file were used to collapse 16 571 probes to 12 357 genes by taking the median intensity of probes representing each gene.

Molecular or biological function pathways and Gene Ontology (GO) gene sets were selected from the molecular signature database (MSigDB) (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>). After filtering gene sets to those with a minimum of 15 and a maximum of 500 gene set size, 294, 439, 209, and 123 gene sets from the Canonical pathways, Biological Process Ontology gene sets, Molecular Function Ontology gene sets, and Cellular Components Ontology gene sets were used in the analysis, respectively.

Examination of age-related changes in microarray isoform ratios with advancing age

We examined the relative balance of alternatively expressed isoforms of selected genes for evidence of disruption to splicing patterns. We first examined the top 50 genes robustly associated with age (Table S1) identified as candidates for study, but only four of them, *ABLIM1*, *CD79A*, *STAT1* and *HSPD1*, showed evidence both of alternative splicing, and expression identified by suitable probes within the expression data available to us. We then selected further genes for study based on the following criteria: the presence of > 5 alternative probes for the same gene, and the presence of > 2 reference isoforms for the gene. The probe sequences were then mapped back onto the specific transcript sequences to determine which probe signals to use for analysis. By these methods, we identified ten genes for study: *ABLIM1*, *CD79A*, *STAT1*, *HSPD1*, *CASP8*, *CLUAP1*, *LAMP2*, *MAX*, *SON*, and *WTAP*. We then carried out a logistic regression of the ratio of signal deriving from isoform-specific probes according to age. Data were adjusted for gender.

TaqMan low-density array (TLDA) assessment of disruption to mRNA splicing

A subset of the cohort comprising the oldest men and women (85–104 years, *n* = 50) was compared with one comprising the youngest men and women (30–44 years, *n* = 50) in this analysis. Total RNA (100 ng) was reversed transcribed in 20- μ L reactions using the Superscript III VILO kit (Invitrogen), according to the manufacturer's instructions. RNA samples were then used for TLDA analysis for transcripts of the *ANXA7*, *BCL11B*, *CXCR5*, *EFNA1*, *GPR18*, *IL6ST*, *PUM1*, and *VCAN* genes, which were selected on the basis that they were alternatively expressed isoforms of genes in the top 250 associations with age which produced a minimum of two isoforms. Endogenous control genes were *IDH3B* and *GUSB*, which were identified as the most stable controls by the GeNORM function of the StatMiner TLDA analysis software (Integro-mics, Granada, Spain). Reaction conditions are described in the Data S1.

Acknowledgments

We thank the many people who contributed to the InCHIANTI study, including all of the anonymous participants. This study was supported in part by the Intramural Research Program, National Institute on Aging and the U.S. National Institutes of Health. We thank Luke Pilling for extra statistical analyses. William Henley completed this work while seconded to PenCLARHC which is funded by the National Institute of Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Author contributions

LWH oversaw the validation experiments, interpreted the data and cowrote the manuscript. DH carried out the microarray experiments. WH oversaw the statistical analysis, carried out the multivariable regression analysis, and contributed to the manuscript. AW carried out initial preprocessing of the data. AH carried out the analysis of differential splicing with age. RBS carried out the TLDA validation of the microarray results. HY carried out the GSEA. AD, TF contributed to the manuscript. AM oversaw the collection and extraction of the RNA samples. JMG aided in design of the InCHIANTI study and contributed to the manuscript. SB oversees the InCHIANTI study and contributed to the manuscript. AS oversaw the microarray experiments. LF organized the sample cohort and contributed to the manuscript. DM managed the project, interpreted the data, cowrote the manuscript, and contributed funding.

References

- Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M (2004) Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. *Ann. Neurol.* **55**, 410–417.
- Ballard FJ, Read LC (1985) Changes in protein synthesis and breakdown rates and responsiveness to growth factors with ageing in human lung fibroblasts. *Mech. Ageing Dev.* **30**, 11–22.
- Butler RN, Miller RA, Perry D, Carnes BA, Williams TF, Cassel C, Brody J, Bernard MA, Partridge L, Kirkwood T, Martin GM, Olshansky SJ (2008) New model of health promotion and disease prevention for the 21st century. *BMJ* **337**, a399.
- Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. *Nat. Rev. Genet.* **3**, 285–298.
- Chen S, Townsend K, Goldberg TE, Davies P, Conejero-Goldberg C (2010) MAPT isoforms: differential transcriptional profiles related to 3R and 4R splice variants. *J. Alzheimers Dis.* **22**, 1313–1329.
- Dai MS, Sun XX, Lu H (2010) Ribosomal protein L11 associates with c-Myc at 5 S rRNA and tRNA genes and regulates their expression. *J. Biol. Chem.* **285**, 12587–12594.
- Debey-Pascher S, Eggle D, Schultze JL (2009) RNA stabilization of peripheral blood and profiling by bead chip analysis. *Methods Mol. Biol.* **496**, 175–210.
- Desai A, Grolleau-Julius A, Yung R (2010) Leukocyte function in the aging immune system. *J. Leukoc. Biol.* **87**, 1001–1009.
- Dumeaux V, Olsen KS, Nuel G, Paulssen RH, Borresen-Dale AL, Lund E (2010) Deciphering normal blood gene expression variation – the NOWAC postgenome study. *PLoS Genet.* **6**, e1000873.
- Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. *Nature* **423**, 293–298.
- Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. *J. Am. Geriatr. Soc.* **48**, 1618.

- Fong N, Bentley DL (2001) Capping, splicing, and 3' processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD. *Genes Dev.* **15**, 1783–1795.
- Gensler HL, Bernstein H (1981) DNA damage as the primary cause of aging. *Q. Rev. Biol.* **56**, 279–303.
- Gruver AL, Hudson LL, Sempowski GD (2007) Immunosenescence of ageing. *J. Pathol.* **211**, 144–156.
- Gu B, Bessler M, Mason PJ (2009) Dyskerin, telomerase and the DNA damage response. *Cell Cycle* **8**, 6–10.
- Hong MG, Myers AJ, Magnusson PK, Prince JA (2008) Transcriptome-wide assessment of human brain and lymphocyte senescence. *PLoS One* **3**, e3024.
- Hsieh FY, Bloch DA, Larsen MD (1998) A simple method of sample size calculation for linear and logistic regression. *Stat. Med.* **17**, 1623–1634.
- Idaghdour Y, Czika W, Shianna KV, Lee SH, Visscher PM, Martin HC, Miclaus K, Jadhav SJ, Goldstein DB, Wolfinger RD, Gibson G (2010) Geographical genomics of human leukocyte gene expression variation in southern Morocco. *Nat. Genet.* **42**, 62–67.
- Keene JD (2010) Minireview: global regulation and dynamics of ribonucleic Acid. *Endocrinology* **151**, 1391–1397.
- Kennedy BK, Kaerberlein M (2009) Hot topics in aging research: protein translation, 2009. *Aging Cell* **8**, 617–623.
- Kenyon CJ (2010) The genetics of ageing. *Nature* **464**, 504–512.
- Kong Q, Lin CL (2010) Oxidative damage to RNA: mechanisms, consequences, and diseases. *Cell. Mol. Life Sci.* **67**, 1817–1829.
- Lazuardi L, Herndler-Brandstetter D, Brunner S, Laschober GT, Lepperding G, Grubeck-Loebenstein B (2009) Microarray analysis reveals similarity between CD8+ CD28– T cells from young and elderly persons, but not of CD8+ CD28+ T cells. *Biogerontology* **10**, 191–202.
- Lubomirski M, D'Andrea MR, Belkowski SM, Cabrera J, Dixon JM, Amaratunga D (2007) A consolidated approach to analyzing data from high-throughput protein microarrays with an application to immune response profiling in humans. *J. Comput. Biol.* **14**, 350–359.
- de Magalhaes JP, Curado J, Church GM (2009) Meta-analysis of age-related gene expression profiles identifies common signatures of aging. *Bioinformatics* **25**, 875–881.
- Meshorer E, Soreq H (2002) Pre-mRNA splicing modulations in senescence. *Aging Cell* **1**, 10–16.
- Min JL, Barrett A, Watts T, Pettersson FH, Lockstone HE, Lindgren CM, Taylor JM, Allen M, Zondervan KT, McCarthy MI (2010) Variability of gene expression profiles in human blood and lymphoblastoid cell lines. *BMC Genomics* **11**, 96.
- Rodwell GE, Sonu R, Zahn JM, Lund J, Wilhelmy J, Wang L, Xiao W, Mindrinos M, Crane E, Segal E, Myers BD, Brooks JD, Davis RW, Higgins J, Owen AB, Kim SK (2004) A transcriptional profile of aging in the human kidney. *PLoS Biol.* **2**, e427.
- Schlaflfi P, Bortner E, Spielmann P, Wenger RH (2009) The PAS-domain kinase PASKIN: a new sensor in energy homeostasis. *Cell. Mol. Life Sci.* **66**, 876–883.
- Smith DL Jr, Nagy TR, Allison DB (2010) Calorie restriction: what recent results suggest for the future of ageing research. *Eur. J. Clin. Invest.* **40**, 440–450.
- Southworth LK, Owen AB, Kim SK (2009) Aging mice show a decreasing correlation of gene expression within genetic modules. *PLoS Genet.* **5**, e1000776.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550.
- Tang Y, Nee AC, Lu A, Ran R, Sharp FR (2003) Blood genomic expression profile for neuronal injury. *J. Cereb. Blood Flow Metab.* **23**, 310–319.
- Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME (2003) Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. *Cancer Res.* **63**, 6069–6075.
- Valcarcel J, Green MR (1996) The SR protein family: pleiotropic functions in pre-mRNA splicing. *Trends Biochem. Sci.* **21**, 296–301.
- Yannarell A, Schumm DE, Webb TE (1977) Age-dependence of nuclear RNA processing. *Mech. Ageing Dev.* **6**, 259–264.
- Yung R, Mo R, Grolleau-Julius A, Hoeltzel M (2007) The effect of aging and caloric restriction on murine CD8+ T cell chemokine receptor gene expression. *Immun. Ageing* **4**, 8.
- Zahn JM, Sonu R, Vogel H, Crane E, Mazan-Mamczarz K, Rabkin R, Davis RW, Becker KG, Owen AB, Kim SK (2006) Transcriptional profiling of aging in human muscle reveals a common aging signature. *PLoS Genet.* **2**, 1058–1069.
- Zahn JM, Poosala S, Owen AB, Ingram DK, Lustig A, Carter A, Weeraratna AT, Taub DD, Gorospe M, Mazan-Mamczarz K, Lakatta EG, Boheler KR, Xu X, Mattson MP, Falco G, Ko MS, Schlessinger D, Firman J, Kummerfeld SK, Wood WH 3rd, Zonderman AB, Kim SK, Becker KG (2007) AGEMAP: a gene expression database for aging in mice. *PLoS Genet.* **3**, e201.
- Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, Maouche S, Germain M, Lackner K, Rossmann H, Eleftheriadis M, Sinning CR, Schnabel RB, Lubos E, Mennerich D, Rust W, Perret C, Proust C, Nicaud V, Loscalzo J, Hubner N, Tregouet D, Munzel T, Ziegler A, Tiret L, Blankenberg S, Cambien F (2010) Genetics and beyond – the transcriptome of human monocytes and disease susceptibility. *PLoS One* **5**, e10693.

Supporting Information

Additional supporting information may be found in the online version of this article:

Data S1 Methods.

Fig. S1 ROC curves for the discovery and replication sets based on a step-wise logistic regression classification model fitted to 25 genes strongly associated with age.

Fig. S2 Leading edge analysis of the number of shared significant pathways.

Fig. S3 Disruption to ratio of alternatively-expressed isoforms with increasing age as assessed by microarray.

Fig. S4 Disruption to ratio of alternatively-expressed isoforms with increasing age as assessed by real-time PCR.

Table S1 Table of significant probe associations with age in the discovery set, with replication set results.

Table S2 Coefficients for the selected logistic regression classification model fitted to the top 25 genes strongly associated with age.

Table S3 TLDA validation results. Transcript expression levels for each gene are given here, expressed relative to the geometric mean of the endogenous controls.

Table S4 Leading edge analysis of GSEA results.

Table S5 Details of amplification and hybridization batches.

Table S6 Targets for real-time PCR validation of TLDA results.

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.